A research-driven enterprise designing proprietary therapeutics, intelligent delivery systems, and highly specialized scientific consumables, engineered where molecular science meets nanotechnology.
We are not merely a pharmaceutical company, we are a deep-technology enterprise redefining the future of healthcare and scientific consumables.
HSC Spark Innovations is a research-driven pharmaceutical and deep-technology company pioneering the next generation of healthcare innovation across the MENA region. Built on a foundation of advanced pharmaceutical science and next-generation nanotechnology, we operate at the intersection of molecular innovation, deep-tech engineering, and clinical excellence.
Our strategy deliberately transcends the conventional generic market. Instead, we design proprietary formulations, intelligent delivery systems, and highly specialized consumable technologies that establish entirely new categories across Egypt and the wider Middle East.
By integrating pharmaceutical expertise with deep-tech innovation, we create solutions that are scientifically differentiated, clinically superior, and exceptionally difficult to replicate, building a platform where advanced molecular science, nanotechnology, and disruptive healthcare engineering converge to shape the next generation of therapeutic and consumable products.
To pioneer the future of healthcare through the integration of advanced pharmaceutical science, nanotechnology, and deep-tech innovation.
Advanced molecular engineering, nano-enabled technologies, and high-precision manufacturing platforms designed to create scientifically differentiated healthcare solutions.
Frictionless administration, intuitive compliance, precision-driven dosing, and dignified treatment experiences that improve adherence and optimize outcomes.
Continuous investment in deep-tech research, proprietary platforms, and next-generation healthcare consumables that deliver sustainable scientific leadership.
Positioning Egypt and the MENA region as a global hub for pharmaceutical innovation, nanotechnology, and advanced healthcare manufacturing.
A premier pharmaceutical and deep-technology company combining advanced pharmaceutical science with nanotechnology and deep-tech engineering to develop breakthrough therapeutics, intelligent consumables, and proprietary delivery systems for the MENA region.
Through advanced molecular engineering, nanotechnology, and deep-tech innovation, we design and manufacture sophisticated therapeutics, intelligent healthcare consumables, and proprietary delivery platforms with seamless, user-centric application systems.
In a market saturated with undifferentiated generics, we create entirely new therapeutic and healthcare consumable categories where scientific complexity, intellectual property, and continuous R&D establish long-term strategic leadership.
Curated partnerships with world-class life-science suppliers, for research labs, universities, and pharmaceutical companies across Egypt and MENA.
HSC Spark Innovations serves as the regional distribution partner for selected international life-science manufacturers. Every partner is chosen for scientific rigor, product quality, and strategic fit with our research-driven customer base. Our role extends beyond logistics, we provide on-the-ground technical support, application guidance, and long-term relationship management.
A specialist manufacturer of nanoparticle characterization and exosome isolation instrumentation, used by leading research laboratories worldwide for high-precision particle analysis and extracellular vesicle workflows.
One of the world's largest genomics organizations, providing comprehensive sequencing services, clinical diagnostic platforms, and life-science research solutions to academic, clinical, and biotechnology institutions.
A leading global provider of custom antibody discovery, engineering, and production services, alongside a broad portfolio of recombinant proteins and biosimilars for academic and pharmaceutical research.
A comprehensive catalogue of high-quality research antibodies, ELISA kits, proteins, and biochemicals, supported by a dedicated HSC Spark sales team to build strategic, long-term client relationships on the ground.
A Canadian biotechnology specialist in nucleic-acid purification and sample preservation, offering proprietary silicon-carbide column technology for superior RNA, DNA, and protein isolation across clinical and research workflows.
Founded and directed by a research scientist with deep-tech expertise, we evaluate every product line through a rigorous technical lens, not a commercial one.
We build long-term, strategic client relationships through scientifically trained representatives who work directly with researchers, procurement officers, and lab heads, not anonymous catalogues.
We distribute only what aligns with our scientific philosophy: differentiated, high-quality, research-grade products from globally recognized manufacturers.
Headquartered in Cairo with a focused mandate to serve Egypt and the wider MENA market, we bridge global suppliers and regional researchers with cultural and regulatory fluency.
Our engagements are designed as long-term partnerships. We invest in client success because our growth depends on repeat scientific collaboration, not one-off orders.
Distribution is one pillar of our work. As we scale proprietary pharmaceutical and deep-tech products of our own, partner clients gain early visibility into emerging regional innovations.
Six years of platform building. Three years of commercial ramp. Four pathways to 2030.
Below: full-cycle revenue from founding in 2017 through 2025 actual results, with four forward scenarios through 2030, three organic and one assuming a $1M growth round in 2026. The 2017–2022 period reflects the company's R&D and platform phase, when commercial activity averaged under $5,000 per year. Sustained commercial revenue began in 2023, scaling 10× to $100,000 by 2025.
A $1M raise in 2026, deployed across sales team buildout, proprietary product R&D acceleration, and inventory expansion, produces a fundamentally different outcome by 2030. Roughly 2.3× the base case, with proprietary product revenue beginning to contribute meaningfully from 2028 onward.
| Year | Conservative | Base case | Aggressive | Funded ($1M raise) |
|---|---|---|---|---|
| 2026 | $175K · +75% | $250K · +150% | $350K · +250% | $450K · +350% |
| 2027 | $300K · +71% | $600K · +140% | $900K · +157% | $1.15M · +156% |
| 2028 | $525K · +75% | $1.2M · +100% | $1.85M · +106% | $2.5M · +117% |
| 2029 | $850K · +62% | $2.2M · +83% | $3.3M · +78% | $4.7M · +88% |
| 2030 | $1.35M · +59% | $3.5M · +59% | $5.2M · +58% | $8.0M · +70% |
| 5-yr total | $3.2M | $7.75M | $11.6M | $16.8M |
Dr. Mohammed Hesham is a founder and entrepreneur working at the intersection of deep-tech, biotechnology, nanotechnology, and advanced life-science solutions. He is currently pursuing a PhD at Khalifa University with research focused on nanobioscience, exosomes, cancer diagnosis, drug delivery systems, and translational biomedical technologies. He also serves as a research visitor at the American University in Cairo and as an instructor at Khalifa University.
Since founding HSC Spark Innovations in 2017, Dr. Hesham has led the development of scientific supply, research-support, and innovation-driven pharmaceutical initiatives serving academic institutions, biotechnology researchers, and advanced R&D laboratories across the region, driving scientific business development and technology-transfer collaborations alongside the company's commercial expansion.
His scientific experience spans academic research, cross-border research commercialization with universities and biotechnology partners, and the development of innovative kits for nanoparticle characterization using Dynamic Light Scattering (DLS) as a scalable, cost-effective alternative to conventional methods such as TEM and SEM. His contributions include scientific publications, patents, and conference presentations in emerging biomedical technologies.
We don't want to compete in existing markets. We want to create the categories that come next.
HSC Spark operates through a structure combining scientific, technical, and business expertise across biotechnology sourcing, pharmaceutical innovation, academic support, sales operations, and strategic partnerships.
PhD candidate at Khalifa University. Research focused on nanobioscience, exosomes, drug delivery, and translational biomedicine.
Leading the company's technical sales function with direct engagement across research and pharmaceutical clients.
Providing scientific guidance to clients on product selection, application, and integration into research workflows.
Coordinating regulatory pathways, compliance, and operational continuity across the company's import and distribution activities.
Managing supply chain coordination, procurement workflows, and certified storage partner relationships.
Coordinating cross-functional business operations, partner communications, and internal workflows across the team.
Full-time sales force engaging clients directly across Egypt and the wider MENA region.
Senior scientific, regulatory, technical, and business functions led by named domain experts.
Senior scientists and professors affiliated with leading universities and research institutions, plus a broader academic collaborator network.
Researchers, universities, hospitals, and biotechnology laboratories across Egypt and the region.
HSC Spark supports a broad cross-section of the regional scientific community through scientific sourcing, advanced research products, and technical support services. Our client relationships range from academic research groups and university procurement offices to pharmaceutical R&D teams and clinical research collaborators.
In parallel with commercial distribution, HSC Spark is developing proprietary deep-tech and pharmaceutical programs across advanced drug delivery, peptide therapeutics, nanobiotechnology, and translational biomedical applications.
Patient-centric peptide therapeutic platforms engineered for pediatric administration, dosing precision, and adherence-focused delivery experiences.
Engineered nanoparticle systems for targeted, controlled-release delivery of therapeutic payloads with improved pharmacokinetics and tissue specificity.
Extracellular vesicle platforms for diagnostics, drug delivery, and translational medicine, building on the founder's PhD research program at Khalifa University.
Innovative kits for nanoparticle characterization using Dynamic Light Scattering, a scalable, cost-effective alternative to conventional TEM and SEM methods.
Scientifically formulated nutraceutical products combining advanced delivery technology with evidence-based active ingredients. Includes registered folic acid product (registration no. 2940).
Advanced biomaterials and research-grade consumables supporting regenerative medicine workflows and emerging cell-therapy research programs.
Send an enquiry to info@hscspark.com or call our Cairo office. Include your institution, product interest, and project context.
Our scientific team reviews your application, recommends the most suitable products from our partner catalogues, and confirms availability and pricing.
You receive a formal quotation with technical specifications, lead times, and delivery terms aligned with your institutional procurement workflow.
Products are delivered via our GMP-certified logistics partners with documentation and application guidance. Our team remains available for technical follow-up and reorder planning.
GMP-certified pharmaceutical storage and logistics provider supporting compliant handling of sensitive research and pharmaceutical materials.
Pharmaceutical logistics and storage company providing temperature-monitored transport, cold-chain handling, and secure laboratory-grade storage.
We welcome enquiries from academic researchers, university procurement teams, hospital labs, and pharmaceutical R&D groups across Egypt and MENA.